Probiotic Yogurt in Patients With Chronic Cholecystitis
Condition(s) studied
Investigational drug(s) / intervention(s)
Functional GR-5 Probiotic Yogurt: A functional yogurt product provided by Jiangruikang Company, containing the probiotic strain Pediococcus acidilactici GR-5, with zero sucrose. Participants will consume it daily for 30 days.
Placebo Yogurt: An ordinary commercial yogurt product provided by Jiangruikang Company, with zero sucrose but without the GR-5 probiotic. It is identical in appearance, color, smell, and taste to the functional yogurt. Participants will consume it daily for 30 days.
Study summary
Background and Purpose: Chronic cholecystitis is a common disease causing gallbladder inflammation, which is closely related to imbalances in gut bacteria and bile acids. This study aims to investigate whether consuming a special functional yogurt containing the probiotic Pediococcus acidilactici GR-5 can help alleviate the symptoms of chronic cholecystitis.
Study Procedures: Researchers will recruit 50 patients with chronic cholecystitis and randomly divide them into two groups. For 30 days, one group will consume the functional GR-5 probiotic yogurt, while the other group will consume regular commercial yogurt (placebo). During the study period, researchers will use abdominal imaging to check the gallbladder, evaluate clinical symptoms, and collect blood and stool samples at baseline and after the 30-day intervention. The goal is to see if this probiotic yogurt can improve gallbladder health by regulating gut bacteria and bile acid metabolism, potentially providing a new dietary and nutritional option for patients with cholecystitis.
Eligibility
Primary outcome measure(s)
- Change from Baseline in Gallbladder Wall Thickness and Smoothness — Baseline and Day 30
Assessed via abdominal ultrasound.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| School of Life Sciences, Lanzhou University | Lanzhou | Gansu |
More LanZhou University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07654985 on ClinicalTrials.gov ↗ ← All trials in China